Zymeron is a research-based biotechnology company that discover, develop and commercialize innovative technologies to deliver products and solutions with step-change performance. It leverages non-dilutive seed funds to develop core intellectual properties to fill technology gaps and address unmet clinical needs. Zymeron’s preclinical pipeline consists of 1) reformulated and repurposed drug candidates with dual-purpose defense and civilian applications, 2) anti-infective NCEs with novel mechanism of action overcoming multidrug resistance, 3) long lasting drug eluting implants to better manage chronic conditions with full patient compliance. Zymeron developed a novel bone marrow-targeted drug delivery system enabling tissue specific bioavailability. The peptide-drug conjugates have demonstrated to deliver small molecule drugs to treat multiple bone marrow disorders. Zymeron has 16 PhD scientists with 300+ years of post-doctoral academic and industrial experiences. The founders have been leading inventors of medical products on the market or managed technology development division within a public company later acquired by PE firms.